Stable Istotope Labelled Infliximab Biosimilar – Anti-TNF-alpha mAb – Research Grade
Size | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Istotope Labelled Infliximab Biosimilar - Anti-TNF-alpha mAb - Research Grade |
---|---|
Source | DrugBank DB00065 |
Species | Human |
Expression system | Mammalian cells |
Molecular weight | 144kDa |
Purity | >95% |
Buffer | PBS pH7.5 |
Delivery condition | Blue Ice |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | 4°C for short term; -20°C for long term |
Brand | ProteoGenix |
Aliases /Synonyms | Infliximab |
Reference | PX-TA1009-SIL |
Related Products | PX-P4641 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1 |
Clonality | Monoclonal Antibody |
Source | DrugBank DB00065 |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
Isotopic Enrichment | 99% |
Stability | 1 year |
Formula | C6428H9912N1694O1987S46 |
General information about Infliximab
Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease. It is given by slow injection into a vein, typically at six- to eight-week intervals. Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a “chimeric monoclonal antibody”. This product is for research use only.
Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.